- Home
- COEP vs LUNG Comparison
COEP vs LUNG Comparison
Compare COEP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- LUNG
- Stock Information
- Founded
- COEP 2017
- LUNG 1995
- Country
- COEP United States
- LUNG United States
- Employees
- COEP N/A
- LUNG N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- COEP Health Care
- LUNG Health Care
- Exchange
- COEP Nasdaq
- LUNG Nasdaq
- Market Cap
- COEP 62.4M
- LUNG 65.6M
- IPO Year
- COEP N/A
- LUNG 2020
- Fundamental
- Price
- COEP $12.96
- LUNG $1.60
- Analyst Decision
- COEP
- LUNG Buy
- Analyst Count
- COEP 0
- LUNG 7
- Target Price
- COEP N/A
- LUNG $7.66
- AVG Volume (30 Days)
- COEP 45.5K
- LUNG 574.6K
- Earning Date
- COEP 11-12-2025
- LUNG 10-29-2025
- Dividend Yield
- COEP N/A
- LUNG N/A
- EPS Growth
- COEP N/A
- LUNG N/A
- EPS
- COEP N/A
- LUNG N/A
- Revenue
- COEP $263,555.00
- LUNG $90,549,000.00
- Revenue This Year
- COEP N/A
- LUNG $10.30
- Revenue Next Year
- COEP N/A
- LUNG $14.72
- P/E Ratio
- COEP N/A
- LUNG N/A
- Revenue Growth
- COEP N/A
- LUNG 18.24
- 52 Week Low
- COEP $2.31
- LUNG $1.47
- 52 Week High
- COEP $14.70
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- COEP 54.10
- LUNG 40.25
- Support Level
- COEP $12.09
- LUNG $1.60
- Resistance Level
- COEP $13.53
- LUNG $1.76
- Average True Range (ATR)
- COEP 0.74
- LUNG 0.14
- MACD
- COEP -0.12
- LUNG 0.03
- Stochastic Oscillator
- COEP 56.55
- LUNG 10.00
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.